retatrutide clinical trials phase 3 Retatrutide FDA Approval Status 2026: Everything We Know So Far

VisualAbstract: Retatrutide reduces body weight by 17.5% in patients with obesity

23.17

★★★★☆4.8 (126)

What GLP‑3 Really Is: Retatrutide Triple‑Receptor Drug

22.56

★★★★★4.9 (98)

The Short | Eli Lilly's Phase 3 clinical trial for retatrutide, a GLP-1 drug, met its primary endpoints, showing a 15.3% improvement in outcomes

20.52

★★★★★5.0 (157)

History in the making. 🚨 Eli Lilly just released late-stage data on their next-gen drug, Retatrutide, and the numbers are redefining what is possible in medicine. We aren't just looking at weight

29.58

★★★★★4.7 (84)

First-in-Class 'Triple-G'! Retatrutide, a first-in-class GIP, GLP-1 & Glucagon triple hormone receptor agonist drug leads to nearly 29% weight loss in first pivotal test! Eli Lilly announced positive topline results from the

22.57

★★★★★4.9 (203)

Reta clinical trial data & dosing — a must read Retatrutide (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP,

21.34

★★★★★5.0 (176)

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

21.20

★★★★★4.8 (132)